SAN DIEGO, Calif. — January 3, 2026 — Fluxion Therapeutics, a Physiomics™ company, today announced the appointment of Vince Groppi, Ph.D., to its Scientific Advisory Board. Dr. Vince Groppi brings over three decades of leadership in neuroscience drug discovery, specialized assay development, and translational biomarkers to Fluxion. Dr. Groppi’s career is defined by foundational contributions to ion channel screening. He was a co-inventor of the FLIPR platform , the industry

ANN ARBOR, MI — January 2, 2026 — Fluxion Therapeutics and the Center for Chemical Genomics (CCG) at the University of Michigan have entered a two-year research collaboration to develop artificial intelligence (AI) and machine learning (ML) models for the automated analysis of ion channel electrophysiology. The partnership combines Fluxion’s proprietary AI-driven analytics with the CCG’s high-throughput screening (HTS) infrastructure. Together, the organizations will develop